Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • PARP
    (10)
  • Apoptosis
    (6)
  • Caspase
    (5)
  • Autophagy
    (2)
  • Bcl-2 Family
    (2)
  • PI3K
    (2)
  • Parasite
    (2)
  • p38 MAPK
    (2)
  • Androgen Receptor
    (1)
  • Others
    (8)
Filter
Search Result
Results for "

parp-1-in-3

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    27
    TargetMol | Inhibitors_Agonists
  • Dye Reagents
    1
    TargetMol | Dye_Reagents
  • Natural Products
    5
    TargetMol | Natural_Products
  • Recombinant Protein
    2
    TargetMol | Recombinant_Protein
PARP-1-IN-3
T781572976342-33-1
PARP-1-IN-3 is a potent PARP-1 inhibitor that inhibits PARP-1 and PARP-2 with IC50 values of 0.25 nM and 2.34 nM, respectively.PARP-1-IN-3 has potential anti-inflammatory activity, induces apoptosis, and arrests the cell cycle in the G2 M phase.PARP-1-IN-3 may be useful for the study of cancer-related diseases. cancer-related diseases.
  • Inquiry Price
8-10 weeks
Size
QTY
TargetMol | Inhibitor Sale
PARP-1-IN-32
T200950374069-33-7
PARP-1-IN-32 (compound 15) is an inhibitor of poly (ADPribose) polymerase-1 (PARP-1), specifically designed for use in cancer research.
  • Inquiry Price
3-6 months
Size
QTY
Dehydrocorydaline
Dehydrocorydalin, 13-Methylpalmatine
T5S235830045-16-0
1. Dehydrocorydaline (13-Methylpalmatine) exerts anti-metastatic potential via suppression of MMPs and Bcl-2 signaling in NSC-LC cells. 2. Dehydrocorydaline stimulates p38 MAPK activation, which can enhance heterodimerization of MyoD and E proteins, thus resulting in MyoD activation and myoblast differentiation. 3. Dehydrocorydaline shows antiplatelet effects, it inhibits thrombin-induced platelet aggregation in a low dose ( IC50= 34.914 ug mL). 4. Dehydrocorydaline has anti-inflammatory and antinociceptive effects. 5. Dehydrocorydaline inhibits MCF-7 cell proliferation by inducing apoptosis mediated by regulating Bax Bcl-2, activating caspases as well as cleaving PARP.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
CSRM617 hydrochloride
CSRM617 hydrochloride(787504-88-5 Free base)
T10896L1353749-74-2In house
CSRM617 hydrochloride is a selective small-molecule inhibitor of the transcription factor ONECUT2 (OC2, a master regulator of androgen receptor), with a Kd of 7.43 µM in SPR assays, directly binding to the OC2-HOX domain. CSRM617 hydrochloride induces apoptosis through the appearance of cleaved Caspase-3 and PARP and is well tolerated in the mouse model of prostate cancer [1].
  • Inquiry Price
7-10 days
Size
QTY
3-Aminobenzamide
PARP-IN-1, INO-1001, INO1001, INO 1001, 3-ABA, 3-AB
T63293544-24-9
3-Aminobenzamide (PARP-IN-1) is a potent PARP inhibitor (IC50 < 50 nM in CHO cells) and mediates oxidant-induced myocyte dysfunction during reperfusion.
  • Inquiry Price
Size
QTY
L-Chicoric Acid
Chicoric acid, trans-Caffeoyltartaric acid, (-)-Chicoric acid, dicaffeoyltartaric acid
T6S239170831-56-0
L-Chicoric Acid (trans-Caffeoyltartaric acid) has been shown to inhibit hyaluronidase and HIV-1 integrase, and to possess phagoeytosis stimulatory activity in vitro and in vivo and antiviral acitivy. L-Chicoric acid may reduce acute alcohol-induced steatosis in mice through interfering with the induction of iNOS and iNOS-dependent signaling cascades in the liver. 3. L-Chicoric acid inhibited cell viability and induced apoptosis in 3T3-L1 preadipocytes which was characterized by chromatin condensation and poly ADP-ribose-polymerase (PARP) cleavage.
  • Inquiry Price
Size
QTY
PARP/PI3K-IN-1
T123652337386-47-5
PARP PI3K-IN-1 is a novel dual poly (ADP-ribose) polymerase (PARP) and phosphatidylinositol 3-kinase (PI3K) dual inhibitor with anticancer, antitumour and antiproliferative activities for the study of breast, pancreatic and lung cancers.
  • Inquiry Price
6-8 weeks
Size
QTY
Tubulin polymerization-IN-68
T2001672924156-96-5
Tubulin polymerization-IN-68 (compound 32) serves as a tubulin inhibitor, disrupting cellular microtubule networks by hindering tubulin polymerization. It also upregulates PARP-1 and caspase-3 expression, thereby inducing apoptosis and exhibiting anticancer properties. Notably, Tubulin polymerization-IN-68 effectively suppresses HepG2 cells with an IC50 of 93 nM and markedly reduces the growth of HepG2 xenograft tumors in nude mice through oral administration.
  • Inquiry Price
2-4 weeks
Size
QTY
AZ9482
T222641825345-33-2
AZ9482 is a selective and potent inhibitor of PARP featuring an amide linkage to a 2-piperazinyl-3-cyano-pyridine. AZ9482 exhibits very potent activity of centrosome declustering with EC50 of < 18 nM in HeLa cells.
  • Inquiry Price
Size
QTY
Dehydrocorydaline nitrate
T2S236213005-09-9
1. Dehydrocorydaline(DHC) not only inhibits antibody-mediated allergic reactions but also influences cell-mediated allergic reactions, and the inhibitory effect of Corydalis Tuber on allergic reactions may be partially attributed to DHC. 2. Dehydrocorydal
  • Inquiry Price
7-10 days
Size
QTY
CAY10760
T36703391889-85-3
CAY10760 is an inhibitor of the protein-protein interaction between RAD51 recombinase and BRCA2 (EC50= 19 μM in a cell-free competitive ELISA).1It decreases homologous recombination by 54% in wild-typeBRCA2-expressing BxPC-3 pancreatic cancer cells when used at a concentration of 20 μM. CAY10760 (20 μM) decreases proliferation of BxPC-3, as well as mutantBRCA2-expressing Capan-1, cancer cells when used alone or in combination with the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib . 1.Bagnolini, G., Milano, D., Manerba, M., et al.Synthetic lethality in pancreatic cancer: Discovery of a new RAD51-BRCA2 small molecule disruptor that inhibits homologous recombination and synergizes with olaparibJ. Med. Chem.63(5)2588-2619(2020)
  • Inquiry Price
6-8 weeks
Size
QTY
5,7-Dihydroxychromone
5,7-Dihydroxy-4H-Chromen-4-One
T5S180531721-94-5
1. 5,7-Dihydroxychromone (5,7-Dihydroxy-4H-Chromen-4-One) isolated from DME is one of the active compounds that may contribute to regulate blood glucose levels. 2. 5,7-Dihydroxychromone exerts neuroprotective effect against 6-OHDA-induced oxidative stress and apoptosis by activating Nrf2 ARE signal . 3. 5,7-Dihydroxychromone induces the translocation of Nrf2 to the nucleus and increases Nrf2 ARE binding activity which results in the up-regulation of the expression of Nrf2-dependent antioxidant genes, including HO-1, NQO1, and GCLc.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
lcs-1
LCS1
T6038641931-13-9
LCS-1 is a selective superoxide dismutase 1 (SOD1) inhibitor and pyridazin-3-one derivative that displays trypanocidal activity at high concentrations.LCS-1 inhibits superoxide dismutase 1 inducing ROS-dependent death and degrading PARP and BRCA1 in glioma cells.
  • Inquiry Price
7-10 days
Size
QTY
rucaparib hydrochloride
T61335773059-19-1
Rucaparib hydrochloride, also known as AG014699, is a powerful and orally active compound that inhibits PARP proteins including PARP-1, PARP-2, and PARP-3 with a Ki value of 1.4 nM for PARP1. Additionally, Rucaparib hydrochloride acts as a modest inhibitor of hexose-6-phosphate dehydrogenase (H6PD). This compound shows potential in research for castration-resistant prostate cancer (CRPC) [1] [2] [3] [4].
  • Inquiry Price
1-2 weeks
Size
QTY
rucaparib acetate
T61657773059-23-7
Rucaparib (AG014699) acetate is a highly effective oral inhibitor of PARP proteins, specifically targeting PARP-1, PARP-2, and PARP-3, with a Ki value of 1.4 nM for PARP1. Additionally, it exhibits inhibitory action on hexose-6-phosphate dehydrogenase (H6PD) to a moderate extent. Rucaparib acetate shows promise in the field of research for castration-resistant prostate cancer (CRPC). [1] [2] [3] [4]
  • Inquiry Price
1-2 weeks
Size
QTY
rucaparib tartrate
T63065773059-22-6
Rucaparib (AG014699) tartrate is an orally active inhibitor of PARP proteins (PARP-1, PARP-2, and PARP-3) and acts on PARP-1 (Ki: 1.4 nM). It is also a hexose hexaphosphate dehydrogenase (H6PD) inhibitor and has potential for use in the study of destructive resistant prostate cancer (CRPC).
  • Inquiry Price
1-2 weeks
Size
QTY
Anticancer agent 64
T635222387902-92-1
Anticancer agent 64 (compound 5m) exhibits potent cytotoxicity against CCRF-CEM cells with an IC50 value of 2.4 μM, induces apoptosis by activating caspase 3 and 7 and causing PARP cleavage, and significantly disrupts mitochondrial membrane potential, thereby contributing to its anticancer efficacy [1].
  • Inquiry Price
10-14 weeks
Size
QTY
rucaparib camsylate
T642891327258-57-0
Rucaparib (AG014699) camsylate is an orally active inhibitor of PARP proteins (PARP-1, PARP-2, and PARP-3) with a Ki=1.4 nM for PARP-1, and also inhibits hexose hexaphosphate dehydrogenase (H6PD). Rucaparib camsylate has potential for investigation in debulking resistant prostate cancer (CRPC) studies.
  • Inquiry Price
6-8 weeks
Size
QTY
AZ6102
T67681645286-75-4
AZ6102 is a potent TNKS1 2 inhibitor that has 100-fold selectivity against other PARP family enzymes and shows IC50 of 5 nM for Wnt pathway inhibition in DLD-1 cells.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
VMY-1-103
T712301209002-43-6
VMY-1-103 is a potent CDK inhibitor, is also a novel dansylated analog of purvalanol B, was shown to inhibit cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B. VMY-1-103 , but not purvalanol B, significantly decreased the proportion of cells in S phase and increased the proportion of cells in G(2) M. VMY-1-103 increased the sub G(1) fraction of apoptotic cells, induced PARP and caspase-3 cleavage and increased the levels of the Death Receptors DR4 and DR5, Bax and Bad while decreasing the number of viable cells, all supporting apoptosis as a mechanism of cell death. VMY-1-103 possesses unique antiproliferative capabilities and that this compound may form the basis of a new candidate drug to treat medulloblastoma.
  • Inquiry Price
6-8 weeks
Size
QTY
parp-2/1-in-2
T72862912444-01-0
PARP-2 1-IN-2, an enantiomer of Veliparib, serves as a potent inhibitor of PARP, demonstrating inhibition constants (Kis) of 2 nM for PARP-2 and 5 nM for PARP-1. This compound exhibits a half-maximal effective concentration (EC50) of 3 nM in cell-based assays evaluating PARP activity [1].
  • Inquiry Price
6-8 weeks
Size
QTY
Anticancer agent 137
T79482
Anticancer agent 137 (8q), a potent PI3k inhibitor, exhibits broad-spectrum anticancer activity by inducing G2 M cell cycle arrest and apoptosis. It increases levels of cleaved PARP, and caspases 3 and 7, making it useful in cancer research [1].
  • Inquiry Price
Size
QTY
JMJD3/HDAC-IN-1
T797132883046-06-6
Compound A5b, also known as JMJD3 HDAC-IN-1, is a dual inhibitor that targets both JMJD3 (Jumonji domain-containing protein demethylase 3) and HADC1 (histone deacetylase, IC50 = 16 nM). It induces hypermethylation of histone H3K27 and hyperacetylation of H3K9, while also promoting apoptosis through the cleavage of caspase-7 and PARP. This compound has demonstrated the ability to effectively inhibit cancer cell cloning, migration, and invasion [1].
  • Inquiry Price
8-10 weeks
Size
QTY
Immunosuppressant-1
T797911224571-03-2
Immunosuppressant-1 (Compound 31) suppresses T-cell proliferation triggered by anti-CD3 anti-CD28 co-stimulation and demonstrates immunosuppressive effects, including the induction of apoptosis in activated lymph node cells through caspase-3 and PARP activation [1].
  • Inquiry Price
8-10 weeks
Size
QTY